Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc., No. 15-1456 (Fed. Cir. Mar. 18, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

These appeals involve two actions brought in the Di s- trict of Delaware against generic drug manufacturer Mylan Pharmaceuticals Inc. One , assigned to Chief Judge Stark, was brought by brand -name drug manufa c- turers Acorda Therapeutics Inc. and Alkermes Pharma ACORDA THERAPEUTICS INC. v. MYLAN PHARM. INC. 4 Ireland Ltd. ; the other , assigned to Judge Sleet, was brought by brand-name drug manufacturer AstraZene ca AB. The plaintiffs brought the actions under 35 U.S.C.